Phase 3 Clinical Trials With Primary Completion Dates in January 2019

This is a list of Phase 3 trials with primary completion dates in January 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AXSM Axsome Therapeutics, Inc. 2019-01-01 Phase 3 NCT02741791 A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
AXSM Axsome Therapeutics, Inc. 2019-01-01 Phase 3 NCT02504008 CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
CANF Can-Fite Biopharma Ltd 2019-01-01 Phase 3 NCT02647762 CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
EYEN Eyenovia, Inc. 2019-01-01 Phase 3 NCT03751631 Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
EYEN Eyenovia, Inc. 2019-01-01 Phase 3 NCT03751098 Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
GKOS Glaukos Corporation 2019-01-01 Phase 3 NCT01461278 Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery
JAZZ Jazz Pharmaceuticals plc 2019-01-01 Phase 3 NCT03030599 A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
LIVN LivaNova PLC 2019-01-01 Phase 3 NCT03279484 Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector
MNK Mallinckrodt plc 2019-01-01 Phase 3 NCT02321319 Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients
OSMT Osmotica Pharmaceuticals plc 2019-01-01 Phase 3 NCT03290131 A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
PCRX Pacira Pharmaceuticals, Inc. 2019-01-01 Phase 3 NCT02740114 Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
RARE Ultragenyx Pharmaceutical Inc. 2019-01-01 Phase 3 NCT02432144 A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
RARE Ultragenyx Pharmaceutical Inc. 2019-01-01 Phase 3 NCT03581591 Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets